Reports
Sale
Philippines Oral Anti-Diabetic Drug Market Size, Share: By Type: Biguanides, Alpha-Glucosidase Inhibitors, Dopamine D-2 Receptor Agonist, Bromocriptine, SGLT-2 Inhibitors, DPP-4 Inhibitors, Sulfonylureas, Meglitinides; By Indication: Diabetes 1, Diabetes 2; By Application; By Distribution Channel; Supplier Landscape; 2024-2032
Philippines Oral Anti-Diabetic Drug Market Outlook
The Philippines oral anti-diabetic drug market is expected to grow at a CAGR of 4.4% during the forecast period of 2024-2032, driven by the increasing prevalence of diabetes along with the rising awareness about diabetes therapeutics in the region.
Philippines Oral Anti-Diabetic Drug Market Overview
In the Philippines, diabetes is the fourth leading cause of mortality, with the incidence of the disease sharply rising in people more than 40 years of age. It is predicted that 5.2 million Filipino adults will have diabetes by 2030. In the Westen Pacific region, the incidence is estimated to affect around 260 million people by 2045. The chronic disease can result in kidney failures, blindness, stroke, and lower limb amputation. It is usually characterized by hyperglycemia (raised blood glucose) that can cause severe damage to the blood vessels and nerves. The rising prevalence and incidence of diabetes in the Philippines have surged the demand for effective therapeutics. Consequently, this will accelerate the Philippines oral anti-diabetic drug market growth in the coming years.
The consumption of unhealthy food and sedentary lifestyles are the major factors contributing to the growing diabetic population in the region. As the inclination towards processed foods is constantly rising, the need for improved and cost-effective anti-diabetic drugs will continue to grow. The key drivers of the market also include the increased approvals of oral anti-diabetic drugs by the health regulatory agencies and the release of new drugs into the market to meet the demands of diabetic patients. Additionally, government-led initiatives and programs to improve the healthcare system and facilitate better accessibility to healthcare facilities are expected to propel the Philippines oral anti-diabetic drug market share in the forecast period.
Surge in Oral Anti-Diabetic Drug Approvals
There has been a significant surge in approvals by health regulatory bodies related to oral anti-diabetic drugs, which are expected to provide more flexibility and wider opportunities to major pharmaceutical companies in the country. In June 2023 , the Food and Drug Administration (FDA) approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin hydrochloride) developed by the leading pharmaceutical firms Eli Lilly and Boehringer Ingelheim. These oral medicines can be used to treat Type 2 diabetes in children aged 10 years or above. Jardiance and Synjardy are the only oral drugs available for children besides metformin that can help regulate blood sugar in pediatric patients, along with dietary adjustments and exercise.
Increased Accessibility to Drugs to Meet the Rising Philippines Oral Anti-Diabetic Drug Market Demand
Several leading pharmaceutical firms offering oral anti-diabetic drug candidates are tapping into emerging economies such as the Philippines where the demand for anti-diabetes drugs is extremely high. One of the significant market trends is the increased accessibility to new oral anti-diabetic drugs at competitive prices which will drive market growth in the forecast period. In March 2023, a South Korean-based company Daewoong Pharmaceutical Co., Ltd. announced the submission of a new drug application (NDA) in the Philippines, Thailand, and Indonesia, in the quest to provide a global market for their new diabetes drug Envlo. The first sodium-glucose cotransporter 2 (SGLT2) inhibitor drug has shown impressive blood sugar lowering and other effects required to effectively manage type 2 diabetes. The company intends to expand its market presence by penetrating 50 countries by 2030.
Philippines Oral Anti-Diabetic Drug Market Segmentation
Market Breakup by Type
- Biguanides
- Metformin
- Alpha-Glucosidase Inhibitors
- Dopamine D-2 receptor agonist
- Bromocriptine
- SGLT-2 Inhibitors
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Farxiga/Forxiga (Dapagliflozin)
- Suglat (Ipragliflozin)
- DPP-4 Inhibitors
- Onglyza (Saxagliptin)
- Tradjenta (Linagliptin)
- Vipidia/Nesina (Alogliptin)
- Galvus (Vildagliptin)
- Sulfonylureas
- Meglitinides
Market Breakup by Indication
- Diabetes 1
- Diabetes 2
Market Breakup by Application
- Preventive
- Prediabetes
- Nutrition
- Obesity
- Lifestyle Management
- Treatment/Care
- Diabetes
- Smoking Cessation
- Musculoskeletal Disorders
- Central Nervous System Disorders
- Cardiovascular Disease
- Medication Adherence
- Chronic Respiratory Disorders
- Gastrointestinal Disorders
- Rehabilitation
- Substance Use Disorders & Addiction Management
Market Breakup by Distribution Channel
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Philippines Oral Anti-Diabetic Drug Market Regional Analysis
Manila, (national capital region) is poised to lead the Philippines oral anti-diabetic drug market share in the coming years. The growing market share can be attributed to the growing support from the government to improve healthcare services. In November 2023, World Diabetes Day in Manila was celebrated by conducting diabetes risk and blood sugar screening, awareness lectures, and exercise, among other activities. The day witnessed a free diabetes screening of over 7400 students from 25 public high schools. The program was aimed at raising awareness about diabetes and reducing the growing cases of Filipino diabetic patients expected to reach 7 million by 2030. The arrangement of such events indicates the rising trend of spreading relevant awareness regarding the condition.
Apart from Manila, other parts of the country, such as Baguio City and Central Luzon are witnessing rapid growth due to heightened awareness among patients and healthcare infrastructure developments.
Philippines Oral Anti-Diabetic Drug Market: Competitor Landscape
In August 2023 , a leading global healthcare company Novo Nordisk A/S announced its plan to acquire Inversago Pharma, a Canadian biotechnology company for USD 1.075 billion in cash. The acquisition will involve Inversago’s leading oral CB1 inverse agonist, INV-202, which exhibited weight loss potential in the phase 1b trial and is currently undergoing a phase 2 trial for diabetic kidney disease. Novo Nordisk plans to further investigate the potential of the drug candidate for obesity, diabetes, and other metabolic diseases and reinforce its clinical development pipeline in severe chronic disorders. Such acquisition and merger initiatives to share resources and expertise among the key market players are anticipated to expand the market size in the region.
The key features of the Philippines oral anti-diabetic drug market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Takeda
- Novo Nordisk
- Pfizer
- Eli Lilly and Company
- Janssen Pharmaceuticals
- Astellas
- Boehringer Ingelheim
- Merck and Co.
- AstraZeneca
- Bristol Myers Squibb
- Novartis
- Sanofi
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Indication |
|
| Breakup by Application |
|
| Breakup by Distribution Channel |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Philippines Oral Anti-Diabetic Drug Market Overview
3.1 Philippines Oral Anti-Diabetic Drug Market Historical Value (2017-2023)
3.2 Philippines Oral Anti-Diabetic Drug Market Forecast Value (2024-2032)
4 Philippines Oral Anti-Diabetic Drug Market Dynamics
4.1 Market Drivers and Constraints
4.2 SWOT Analysis
4.2.1 Strengths
4.2.2 Weaknesses
4.2.3 Opportunities
4.2.4 Threats
4.3 Porter’s Five Forces Model
4.3.1 Bargaining Power of Suppliers
4.3.2 Bargaining Power of Buyers
4.3.3 Threat of New Entrants
4.3.4 Threat of Substitutes
4.3.5 Degree of Rivalry
4.4 Key Demand Indicators
4.5 Key Price Indicators
4.6 Industry Events, Initiatives, and Trends
4.7 Value Chain Analysis
5 Philippines Oral Anti-Diabetic Drug Market Segmentation
5.1 Philippines Oral Anti-Diabetic Drug Market by Type
5.1.1 Market Overview
5.1.2 Biguanides
5.1.2.1 Metformin
5.1.3 Alpha-Glucosidase Inhibitors
5.1.4 Dopamine D-2 Receptor Agonist
5.1.5 Bromocriptine
5.1.6 SGLT-2 Inhibitors
5.1.6.1 Invokana (Canagliflozin)
5.1.6.2 Jardiance (Empagliflozin)
5.1.6.3 Farxiga/Forxiga (Dapagliflozin)
5.1.6.4 Suglat (Ipragliflozin)
5.1.7 DPP-4 Inhibitors
5.1.7.1 Onglyza (Saxagliptin)
5.1.7.2 Tradjenta (Linagliptin)
5.1.7.3 Vipidia/Nesina(Alogliptin)
5.1.7.4 Galvus (Vildagliptin)
5.1.8 Sulfonylureas
5.1.9 Meglitinides
5.2 Philippines Oral Anti-Diabetic Drug Market by Indication
5.2.1 Market Overview
5.2.2 Diabetes 1
5.2.3 Diabetes 2
5.3 Philippines Oral Anti-Diabetic Drug Market by Application
5.3.1 Market Overview
5.3.2 Preventive
5.3.2.1 Prediabetes
5.3.2.2 Nutrition
5.3.2.3 Obesity
5.3.2.4 Lifestyle Management
5.3.3 Treatment/Care
5.3.3.1 Diabetes
5.3.3.2 Smoking Cessation
5.3.3.3 Musculoskeletal Disorders
5.3.3.4 Central Nervous System Disorders
5.3.3.5 Cardiovascular Disease
5.3.3.6 Medication Adherence
5.3.3.7 Chronic Respiratory Disorders
5.3.3.8 Gastrointestinal Disorders
5.3.3.9 Rehabilitation
5.3.3.10 Substance Use Disorders & Addiction Management
5.4 Philippines Oral Anti-Diabetic Drug Market by Distribution Channel
5.4.1 Online Pharmacies
5.4.2 Hospital Pharmacies
5.4.3 Retail Pharmacies
6 Patent Analysis
6.1 Analysis by Type of Patent
6.2 Analysis by Publication Year
6.3 Analysis by Issuing Authority
6.4 Analysis by Patent Age
6.5 Analysis by CPC Analysis
6.6 Analysis by Patent Valuation
6.7 Analysis by Key Players
7 Grants Analysis
7.1 Analysis by Year
7.2 Analysis by Amount Awarded
7.3 Analysis by Issuing Authority
7.4 Analysis by Grant Application
7.5 Analysis by Funding Institute
7.6 Analysis by NIH Departments
7.7 Analysis by Recipient Organization
8 Funding Analysis
8.1 Analysis by Funding Instances
8.2 Analysis by Type of Funding
8.3 Analysis by Funding Amount
8.4 Analysis by Leading Players
8.5 Analysis by Leading Investors
8.6 Analysis by Geography
9 Partnership and Collaborations Analysis
9.1 Analysis by Partnership Instances
9.2 Analysis by Type of Partnership
9.3 Analysis by Leading Players
9.4 Analysis by Geography
10 Regulatory Framework
10.1 Regulatory Overview
11 Supplier Landscape
11.1 Takeda
11.1.1 Financial Analysis
11.1.2 Product Portfolio
11.1.3 Demographic Reach and Achievements
11.1.4 Mergers and Acquisitions
11.1.5 Certifications
11.2 Novo Nordisk
11.2.1 Financial Analysis
11.2.2 Product Portfolio
11.2.3 Demographic Reach and Achievements
11.2.4 Mergers and Acquisitions
11.2.5 Certifications
11.3 Pfizer
11.3.1 Financial Analysis
11.3.2 Product Portfolio
11.3.3 Demographic Reach and Achievements
11.3.4 Mergers and Acquisitions
11.3.5 Certifications
11.4 Eli Lilly and Company
11.4.1 Financial Analysis
11.4.2 Financial Portfolio
11.4.3 Demographic Reach and Achievements
11.4.4 Mergers and Acquisitions
11.4.5 Certifications
11.5 Janssen Pharmaceuticals
11.5.1 Financial Analysis
11.5.2 Product Portfolio
11.5.3 Demographic Reach and Achievements
11.5.4 Mergers and Acquisitions
11.5.5 Certifications
11.6 Astellas
11.6.1 Financial Analysis
11.6.2 Product Portfolio
11.6.3 Demographic Reach and Achievements
11.6.4 Mergers and Acquisitions
11.6.5 Certifications
11.7 Boehringer Ingelheim
11.7.1 Financial Analysis
11.7.2 Product Portfolio
11.7.3 Demographic Reach and Achievements
11.7.4 Mergers and Acquisitions
11.7.5 Certifications
11.8 Merck and Co.
11.8.1 Financial Analysis
11.8.2 Product Portfolio
11.8.3 Demographic Reach and Achievements
11.8.4 Mergers and Acquisitions
11.8.5 Certifications
11.9 AstraZeneca
11.9.1 Financial Analysis
11.9.2 Product Portfolio
11.9.3 Demographic Reach and Achievements
11.9.4 Mergers and Acquisitions
11.9.5 Certifications
11.10 Bristol Myers Squibb
11.10.1 Financial Analysis
11.10.2 Product Portfolio
11.10.3 Demographic Reach and Achievements
11.10.4 Mergers and Acquisitions
11.10.5 Certifications
11.11 Novartis
11.11.1 Financial Analysis
11.11.2 Product Portfolio
11.11.3 Demographic Reach and Achievements
11.11.4 Mergers and Acquisitions
11.11.5 Certifications
11.12 Sanofi
11.12.1 Financial Analysis
11.12.2 Product Portfolio
11.12.3 Demographic Reach and Achievements
11.12.4 Mergers and Acquisitions
11.12.5 Certifications
12 Philippines Oral Anti-Diabetic Drug Market - Distribution Model (Additional Insight)
12.1 Overview
12.2 Potential Distributors
12.3 Key Parameters for Distribution Partner Assessment
13 Key Opinion Leaders (KOL) Insights (Additional Insight)
14 Company Competitiveness Analysis (Additional Insight)
14.1 Very Small Companies
14.2 Small Companies
14.3 Mid-Sized Companies
14.4 Large Companies
14.5 Very Large Companies
15 Payment Methods (Additional Insight)
15.1 Government Funded
15.2 Private Insurance
15.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Key Questions Answered in the Report
The market is anticipated to grow at a CAGR of 4.4% during the forecast period of 2024-2032, driven by the increasing prevalence of diabetes along with the rising awareness about diabetes therapeutics in the region.
The increased acquisitions and mergers initiatives by the key players and the robust support from the government to advance healthcare services are fuelling the demand for oral anti-diabetic drugs.
One of the significant trends in the Philippines market is the significant surge in approvals by health regulatory bodies related to oral anti-diabetic drugs. In June 2023, the Food and Drug Administration (FDA) approved Jardiance and Synjardy by the leading pharmaceutical firms Eli Lilly and Boehringer Ingelheim. These medicines are the only oral drugs available for children besides metformin that can help regulate blood sugar in pediatric patients, along with dietary adjustments and exercise.
Based on the indication, the market is divided into diabetes 1 and diabetes 2.
Based on the type, the market is segmented into biguanides, alpha-glucosidase inhibitors, dopamine D-2 receptor agonists, bromocriptine, SGLT-2 inhibitors, DPP-4 inhibitors, sulfonylureas, and meglitinides. Further, biguanides include metformin, while SGLT-2 inhibitors include invokana (canagliflozin), jardiance (empagliflozin), farxiga/forxiga (dapagliflozin), and suglat (ipragliflozin) and DPP-4 Inhibitors include Onglyza (Saxagliptin), Tradjenta (Linagliptin), Vipidia/Nesina (Alogliptin), and Galvus (Vildagliptin).
Major distribution channels of oral anti-diabetic drugs include online pharmacies, hospital pharmacies, and retail pharmacies.
Oral anti-diabetic drugs are used in prevention and treatment or care. Preventive applications include prediabetes, nutrition, obesity, and lifestyle management while treatment/care comprises diabetes, smoking cessation, musculoskeletal disorders, central nervous system disorders, cardiovascular disease, medication adherence, chronic respiratory disorders, gastrointestinal disorders, rehabilitation, substance use disorders, and addiction management.
Key players involved in the market are Takeda, Novo Nordisk, Pfizer, Eli Lilly and Company, Janssen Pharmaceuticals, Astellas, Boehringer Ingelheim, Merck and Co., AstraZeneca, Bristol Myers Squibb, Novartis, and Sanofi.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2199
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 3299
$2999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 4399
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 5499
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER